PharmaBlock Sciences

What PharmaBlock Sciences does

PharmaBlock Sciences (Stock code: 300725.SZSE) is a publicly listed Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Nanjing, China. Officially operational since 2008, the company provides integrated chemistry products and services spanning drug discovery, development, and commercial manufacturing for global pharmaceutical and biotech clients. Its service portfolio includes novel building blocks, chemistry research services, drug substance CDMO (API and intermediate manufacturing), and drug product CDMO (oral solid dosage forms). The company has reportedly partnered with nearly all of the top 20 global pharmaceutical companies and maintains relationships with approximately 700 global partners across six sites in the United States, China, and Switzerland, supported by a workforce of approximately 2,600 employees.

The company's competitive positioning is anchored in proprietary low-carbon manufacturing technologies: continuous flow chemistry deployed across more than 1,800 development and commercial projects, micropacked bed hydrogenation reactors achieving hundreds of metric tons per year, photo flow reactors with up to 100 kg/day output, biocatalysis, and electrochemistry. It has also built an integrated peptide synthesis platform combining liquid-phase peptide synthesis (LPPS), continuous-flow LPPS (CFLPPS), and enzyme-assisted peptide synthesis (EAPS), culminating in a new peptide GMP pilot-scale plant at its Zhejiang site (operational June 2026). These capabilities earned back-to-back ACS Green Chemistry Awards in 2023 and 2024 and recognition alongside GSK and Boehringer Ingelheim by the ACS Green Chemistry Institute Pharmaceutical Roundtable.

PharmaBlock generates revenue through a project-based enterprise CRDMO model: clients engage PharmaBlock directly on multi-year contracts for chemistry research services, drug substance manufacturing, and drug product manufacturing, with pricing negotiated on a per-project basis. Revenue streams span fee-for-service CDMO engagements, chemistry research services, and transactional sale of novel building blocks. The company's go-to-market is enterprise field sales targeting top-tier pharmaceutical accounts and biotech programs, supported by a professional B2B presence through its corporate website, LinkedIn, WeChat, and industry events. Recent strategic emphasis is on expanding into new molecular modalities (oligonucleotides, peptides, complex conjugates) via the OPC Division, positioning PharmaBlock to capture growth in next-generation therapeutic categories while leveraging its established low-carbon chemistry platforms.

Name

PharmaBlock Sciences

Legal name

PharmaBlock USA Inc

Website

https://pharmablock.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

PharmaBlock is a publicly listed Chinese CRDMO providing chemistry research, drug substance and drug product CDMO services, and novel building blocks to nearly all top 20 global pharmaceutical companies and hundreds of biotechs across six sites in the US, China, and Switzerland.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical CDMO services
• Drug substance manufacturing
• Building block supply
• Continuous flow chemistry
• Peptide synthesis services

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services (Drug Substance & Drug Product): Fee-for-service contract development and manufacturing organization model for APIs, intermediates, and oral solid dosage forms. Revenue is project-based, driven by R&D and GMP manufacturing engagements with pharmaceutical and biotech clients.
2. Chemistry Research Services: Chemistry research services providing efficient access to in-house building blocks for research needs, supporting drug discovery programs for small molecule and new modality compounds.
3. Novel Building Blocks: Sale of novel and diverse building blocks for research needs of small molecule drugs and new modalities, providing a product-based revenue stream alongside service engagements.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PharmaBlock operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) for the pharmaceutical industry, providing novel building blocks for drug discovery, chemistry research services, drug substance CDMO (API and intermediate development and GMP manufacturing), drug product CDMO (oral solid dosage forms), new modalities services (oligonucleotides, peptides, complex conjugates), and CMC regulatory services. Revenue is generated through project-based professional services contracts with global pharmaceutical and biotech clients, supplemented by direct sales of novel building blocks.

Product overview

PharmaBlock is a leading CRDMO (Contract Research, Development, and Manufacturing Organization) providing innovative chemistry products and services throughout the pharmaceutical R&D process and commercial manufacturing. The company operates a multi-site network across the USA, China, and Switzerland with approximately 2,600 employees serving almost all top 20 pharmaceutical companies and hundreds of biotech companies globally. Its portfolio includes Novel Building Blocks for drug discovery, Chemistry Research Services, Drug Substance CDMO (API manufacturing), Drug Product manufacturing (oral solid dosages), and Low-carbon Technology platforms. The company has strategic focus on new molecular modalities through its OPC Division (oligonucleotides, peptides, complex conjugates), supported by integrated technology platforms for peptide synthesis (LPPS, CFLPPS, EAPS) and continuous flow chemistry manufacturing. Founded in 2008, PharmaBlock has grown from building block products to become a comprehensive GMP manufacturing service partner.

Differentiator

Problem solved

Functional benefit

Products and services

• Novel Building Blocks

Quantifiable outcome

• Applied continuous flow chemistry technology across more than 1,800 development and commercial projects.
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hovione: Hovione is a privately-held global CDMO specializing in small molecule API and particle engineering with strong continuous-manufacturing capabilities, directly comparable to PharmaBlock's drug-substance offering and customer base.
• ChemPartner (Pharmaron): ChemPartner is a China-based CRO/CDMO offering integrated chemistry services and drug substance manufacturing for global biopharma, overlapping with PharmaBlock's research services and small molecule CDMO.
• Carbogen Amcis: Carbogen Amcis is a Switzerland-based API CDMO with strong drug substance development and high-potency capabilities, comparable to PharmaBlock's European footprint and small-molecule CMC focus.
• Divi's Laboratories: Divi's is a large India-headquartered API and intermediates manufacturer serving global generics and innovator pharma, comparable in drug substance scale, route-of-synthesis focus, and cost-driven manufacturing model.
• WuXi STA (WuXi AppTec): WuXi STA is WuXi AppTec's small molecule CDMO arm and the largest China-based competitor to PharmaBlock, offering integrated drug substance and drug product CDMO services with similar flow-chemistry and peptide capabilities across a global site network.
• Asymchem Laboratories: Asymchem is a leading China-headquartered CDMO providing API/intermediate development and manufacturing to global pharma, with comparable flow chemistry and green-chemistry positioning and overlapping top-20 pharma clients.

Broad incumbents

• Catalent (Thermo Fisher Scientific): Catalent, now part of Thermo Fisher, is a global CDMO with leading drug product (oral solids, softgel, sterile) capabilities, directly comparable to PharmaBlock's drug-product CDMO and top-20 pharma client base.
• Lonza Group: Lonza is the world's largest CDMO with broad small molecule, biologics, peptide and cell-and-gene therapy capabilities; a much larger incumbent that competes with PharmaBlock across the integrated DS+DP and peptide CDMO services.
• Siegfried Holding: Siegfried is a Switzerland-based CDMO with API and drug product manufacturing for innovator and generic pharma, comparable to PharmaBlock's drug substance/drug product integrated model and European presence.

Emerging players

• Aurigene Pharmaceutical Services: Aurigene is an India-based emerging CRDMO with growing small molecule API and biologics offerings serving biotech and large pharma, providing meaningful partial overlap with PharmaBlock's chemistry services and new modality expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmablock

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaBlock Sciences